EUVIMED · CrossrefZeitschrift
Canadian Hematology Today
ISSN 2816-5160 · Catalytic Health
Neueste Artikel
Fixed-Duration First-Line Therapy for Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) in Canada: A Canadian Expert Clinical Framework
Current Management of Relapsed or Refractory Classic Hodgkin Lymphoma in Canada
Approach to Patients with Acute Myeloid Leukemia in First Relapse: A Practical Guide for Canadian Hematologists
Upfront Therapy for Non‑transplantable Multiple Myeloma in 2026: Decision‑making in an Increasingly Complex Therapeutic Landscape
Is Continuous Therapy Becoming Finite? The Evolving Landscape of CLL Treatment in 2026
High-Risk Multiple Myeloma in 2026: Evolving Definitions and Therapeutic Options
Not All Bruton's Tyrosine Kinase Inhibitors are Created Equal: Pharmacologic Insights into the Efficacy, Resistance, and Safety of Covalent and Non-covalent BTK Inhibitors
Emerging therapeutic agents in the treatment of relapsed or refractory diffuse large B cell lymphoma
Next-generation sequencing for myeloid malignancies
Management of follicular lymphoma at first relapse
Myeloproliferative neoplasms in 2022
Diagnosis and treatment of AL amyloidosis in 2022
To transplant or not to transplant in multiple myeloma
Immunotherapy in Hodgkin lymphoma
Tailoring therapy in Waldenström Macroglobulinemia
Multiple myeloma management: What comes after lenalidomide-based therapy?
Chimeric antigen receptor T-cell therapy for relapsed and refractory large B-cell lymphoma
With great power comes great responsibility: Managing side effects of novel treatments in chronic lymphocytic leukemia (CLL)
Moving beyond chemotherapy in the management of follicular lymphoma
The evolving treatment landscape of higher-risk MDS
Evolving strategies in T-cell lymphoma
Hereditary hematologic malignancies: a Canadian perspective
Chronic Myeloid Leukemia: who should get a treatment-free trial and how?
Safety and tolerability of Bruton's tyrosine kinase inhibitors in the treatment of Waldenström macroglobulinemia
Treatment options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients
Expert clinical framework report: Management of adverse events related to novel therapies for relapsed/refractory multiple myeloma (RRMM)
Updates in the treatment of mantle cell lymphoma: A Canadian expert framework
Frontline management of transplant-ineligible newly diagnosed multiple myeloma (TINDMM) in Canada
Controversies and current practices in CNS relapse of diffuse large B-cell lymphoma
Management of limited stage Hodgkin lymphoma
EUVIMED